[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100475728":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":10,"locations":25,"responsibleParty":38,"collaborators":10,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":10,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":56,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":65,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Kanuni Sultan Suleyman Training and Research Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"AUK with Dydrogestrone",null,"Patients who applied for abnormal uterine bleeding and received oral dydrogesterone therapy for at least 6 months",[13],"Other: SF-36 Scores",{"label":15,"type":10,"description":16,"interventionNames":17},"AUK with Levonorgestrel releasing intrauterin device","Patients who applied for abnormal uterine bleeding and were administered levonorgestrel-releasing intrauterine device at least 6 months ago",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"SF-36 Scores","From the electronic database system of our hospital, patients who applied to the gynecology polyclinics of our hospital due to abnormal uterine bleeding between August 2020 and December 2021 and were administered oral dydrogesterone therapy or an intrauterine device releasing levonorgestrel for at least six months were reached using the phone numbers registered in the system.\n\nThe patients were informed about the study conducted by teleconference method, and the patients whose verbal consent was obtained were included in the study. After questioning the patients' sociodemographic characteristics such as age, marital status, educational status, income level, employment status, and obstetric history, the patients received the Short form 36 (P-36), consisting of 36 items; The Quality of Life Scale and the Female Sexual Function Scale (FSFI) composed of 19 items were applied.",[9,15],[24],"FSFI scores",[26],{"facility":27,"status":10,"city":28,"state":29,"zip":30,"country":31,"countryCode":10,"cosmosGeoPoint":32,"geoPoint":37,"contacts":10},"Pinar Yalcin Bahat","Istanbul","İ̇stanbul","34000","Turkey (Türkiye)",{"type":33,"coordinates":34},"Point",[35,36],28.94966,41.01384,{"lat":36,"lon":35},{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Pınar Yalcin bahat","Principial investigator","100475728","evaluation-of-the-effects-of-levonorgestrel-releasing-intrauterine-device-and-dydrogestreone-on-quality-of-life-and-sexual-life-in-patients-with-abnormal-uterine-bleeding-100475728",false,"NCT05474703","Evaluation of the Effects of Levonorgestrel-releasing Intrauterine Device and Dydrogestreone on Quality of Life and Sexual Life in Patients With Abnormal Uterine Bleeding.","Evaluating the Effects of Levonorgestrel-releasing Intrauterine Device and Dydrogestreone on Quality of Life and Sexual Life in Patients With Abnormal Uterine Bleeding.","Inclusion Criteria:\n\n* Sexually active patients with abnormal uterine bleeding\n* Patients with no known malignancy history or suspected malignancy, patients with average smear results,\n* Patients without bleeding diathesis,\n* Patients using drugs that may cause vaginal bleeding,\n\nExclusion Criteria:\n\n* Sexually inactive patients\n* Patients in pregnancy or postpartum period,\n* Patients with a known history of malignancy or suspected malignancy, patients with abnormal smear results,\n* Patients with bleeding diathesis,\n* Patients using drugs that may cause vaginal bleeding, patients with any organic pathology to explain the bleeding in gynecological examination\n* Patients with a dislocated levonorgestrel-releasing intrauterine device\n* Patients who have previously received different treatments for abnormal uterine bleeding",true,"FEMALE","18 Years","45 Years",{"count":54,"type":55},171,"ACTUAL","6 Months","OBSERVATIONAL","This study was retrospectively collected from patients who were diagnosed with abnormal uterine bleeding and received oral dydrogesterone therapy for at least six months or who were administered an intrauterine device containing levonorgestrel at least six months ago, and prospectively Short form 36 (P-36); It covers the comparison of the Quality of Life Scale and the Female Sexual Function Scale (FSFI) by asking over the phone.",[60],"Abnormal Uterine Bleeding",[62,63,60,64],"Dydrogesterone","Levonorgestrel","Quality of life","UNKNOWN","2022-07-27",{"date":68,"type":55},"2022-07-29",{"date":70,"type":55},"2022-02-20",{"date":72,"type":73},"2022-08-10","ESTIMATED",{"name":5,"class":6},1]